ゴーシェ病市場 - 機会評価と予測

ゴーシェ病の有病率は、主要7ヶ国市場の人口増加に伴い、AGR 0.39％と着実に増加しています。現在、1型ゴーシェ病と3型ゴーシェ病の治療薬として市販されているのは、ERTとSRT（セレザイム、VPRIV、エレリッソ、セルデルガ、ザベスカ）が主流です。

2型ゴーシェ病や3型ゴーシェ病患者が示す神経障害症状の治療に有効な治療薬がないなど、ゴーシェ病分野にはいくつかのアンメットニーズが存在します。

ゴーシェ病の研究開発パイプラインには、遺伝子治療や初の脳浸透性SRTとなることが期待されるベングルスタットリンゴ酸塩など、革新的な製品がいくつかあります。ゴーシェ病患者数の緩やかな増加と診断アプローチの改善に伴い、予測期間を通じて安定した市場成長が見込まれます。

当レポートでは、主要7ヶ国（米国、欧州5カ国（フランス、ドイツ、イタリア、スペイン、英国）、およびイスラエル）のゴーシェ病市場について調査し、市場の概要とともに、2022年～2032年の市場予測、競合情勢などを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 病気の概要

• ゴーシェ病の概要
• ゴーシェ病SWOT分析
• ゴーシェ病の分類

第4章 疫学

第5章 現在の治療選択肢

• 治療パラダイム
• 現在の治療選択肢
• 製品概要：酵素補充療法（Cerezyme、VPRIV、Elelyso）
• 製品プロファイル：基質減少療法（Zavesca、Cerdelga）
• 現在の治療選択肢-KOLの視点

第6章 アンメットニーズと機会

• ゴーシェ病におけるアンメットニーズ
• 神経障害療法の大幅な不足
• 市販の治療法は高額である
• 不便な治療オプション
• 早期の診断とスクリーニングが必要

第7章 研究開発戦略

• ゴーシェ病における取引の動向
• ゴーシェ病における臨床試験デザインの動向

第8章 パイプラインの評価

第9章 市場の見通し

• ゴーシェ病市場予測
• 市場促進要因と抑制要因

第10章 付録

第11章 お問い合わせ

Abstract

The prevalence of GD is increasing at a steady rate, in line with population growth in the 7MM, at an AGR of 0.39%.

Currently, the marketed treatment regimen for Type 1 GD and Type 3 GD is dominated by ERTs and SRTs (Cerezyme, VPRIV, Elelyso, Cerdelga, Zavesca).

There are several unmet needs in the GD landscape, including the lack of effective therapies for treating the neuropathic manifestations presented by Type 2 GD and Type 3 GD patients.

The GD R&D pipeline offers some innovative products, including gene therapy and venglustat malate, which is expected to be the first brain-penetrant SRT.

Steady market growth is expected throughout the forecast period as the GD population slowly increases and diagnostic approaches improve.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model.

Forecast includes 7MM: US, 5EU (France, Germany, Italy, Spain and the UK) and Israel.

Forecasts cover 2022-2032.

Scope

• Overview of GD, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized GD therapeutics market revenue in 7MM (US, 5EU and Israel), annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GD therapeutics market.
• Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for GD treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM GD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the GD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Gaucher Disease
• 3.2. Gaucher Disease SWOT Analysis
• 3.3. Classification of Gaucher Disease

4. Epidemiology

• 4.1. Diagnosed Prevalent Cases of GD
• 4.2. Diagnosed Prevalent Cases of GD by Type
• 4.3. Sources and Methodology for GD Prevalence
• 4.4. Sources and Methodology for GD

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Current Treatment Options
• 5.3. Product Profile: Enzyme Replacement Therapy (Cerezyme, VPRIV, Elelyso)
• 5.4. Product Profile: Substrate Reduction Therapy (Zavesca, Cerdelga)
• 5.5. Current Treatment Options - KOL Perspective

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Gaucher Disease
• 6.2. Significant Lack of Neuropathic Therapies
• 6.3. Marketed Therapies are Highly Expensive
• 6.4. Inconvenient Treatment Options
• 6.5. Early Diagnosis and Screening is Required

7. R&D Strategies

• 7.1. Trends in Deal-Making in Gaucher Disease
• 7.2. Trends in Clinical Trial Design in Gaucher Disease

8. Pipeline Assessment

• 8.1. Gaucher Disease Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Gaucher Disease
• 8.3. Product Profile: Sanofi's Venglustat malate
• 8.4. Product Profile: Sanofi's Eliglustat tartrate
• 8.5. Product Profile: SZMC-Takeda's Ambroxol
• 8.6. Gaucher Disease Clinical Trials Overview

9. Market Outlook

• 9.1. Gaucher Disease Market Forecast
• 9.2. Market Drivers and Barriers

10. Appendix

• 10.1. Bibliography
• 10.2. About the Authors

11. Contact Us